Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens

被引:129
作者
Chen, JR
Plotkin, LI
Aguirre, JI
Han, L
Jilka, RL
Kousteni, S
Bellido, T
Manolagas, SC
机构
[1] Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA
[2] Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA
关键词
D O I
10.1074/jbc.M411530200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sex steroids exert anti-apoptotic effects on osteoblasts/osteocytes but exert pro-apoptotic effects on osteoclasts, in both cases requiring activation of the extracellular signal-regulated kinases (ERKs). To explain the mechanistic basis of this divergence, we searched for differences in the kinetics of phosphorylation and/or in the subeellular localization of ERKs in response to 17beta-estradiol in the two cell types. In contrast to its transient effect on ERK phosphorylation in osteocytic cells (return to base line by 30 min), 17beta-estradiol-induced ERK phosphorylation in osteoclasts was sustained for at least 24 h following exposure to the hormone. Conversion of sustained ERK phosphorylation to transient, by means of cholera toxin-induced activation of the adenylate cyclase/cAMP/protein kinase A pathway, abrogated the pro-apoptotic effect of 17beta-estradiol on osteoclasts. Conversely, prolongation of ERK activation in osteocytes, by means of leptomycin B-induced inhibition of ERK export from the nucleus or overexpression of a green fluorescent protein-ERK2 mutant that resides permanently in the nucleus, converted the anti-apoptotic effect of 17beta-estradiol to a pro-apoptotic one. These findings indicate that the kinetics of ERK phosphorylation and the length of time that phospho-ERKs are retained in the nucleus are responsible for pro- versus anti-apoptotic effects of estrogen on different cell types of bone and perhaps their many other target tissues.
引用
收藏
页码:4632 / 4638
页数:7
相关论文
共 54 条
[1]   FUNCTION OF OSTEOCYTES IN BONE [J].
AARDEN, EM ;
BURGER, EH ;
NIJWEIDE, PJ .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 55 (03) :287-299
[2]   Common sense signalling [J].
Assoian, RK .
NATURE CELL BIOLOGY, 2002, 4 (08) :E187-E188
[3]   Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells [J].
Balmanno, K ;
Cook, SJ .
ONCOGENE, 1999, 18 (20) :3085-3097
[4]   Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism [J].
Bellido, T ;
Ali, AA ;
Plotkin, LI ;
Fu, Q ;
Gubrij, I ;
Roberson, PK ;
Weinstein, RS ;
O'Brien, CA ;
Manolagas, SC ;
Jilka, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :50259-50272
[5]   REGULATION OF INTERLEUKIN-6, OSTEOCLASTOGENESIS, AND BONE MASS BY ANDROGENS THE ROLE OF THE ANDROGEN RECEPTOR [J].
BELLIDO, T ;
JILKA, RL ;
BOYCE, BF ;
GIRASOLE, G ;
BROXMEYER, H ;
DALRYMPLE, SA ;
MURRAY, R ;
MANOLAGAS, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2886-2895
[6]  
Boyce BF, 2002, PRINCIPLES BONE BIOL, V1, P151
[7]   Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α [J].
Cenci, S ;
Weitzmann, MN ;
Roggia, C ;
Namba, N ;
Novack, D ;
Woodring, J ;
Pacifici, R .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (10) :1229-1237
[8]   Introduction [J].
Yang-Tse Cheng ;
Trevor Page ;
George M. Pharr ;
Michael V. Swain ;
Kathryn J. Wahl .
Journal of Materials Research, 2004, 19 (1) :1-2
[9]   JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms [J].
David, JP ;
Sabapathy, K ;
Hoffmann, O ;
Idarraga, MH ;
Wagner, EF .
JOURNAL OF CELL SCIENCE, 2002, 115 (22) :4317-4325
[10]   Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis [J].
Filardo, EJ ;
Quinn, JA ;
Frackelton, AR ;
Bland, KI .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (01) :70-84